Co-Authors
This is a "connection" page, showing publications co-authored by Andrzej Jakubowiak and Jennifer Cooperrider.
Connection Strength
0.553
-
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 Oct 07; 14(1):170.
Score: 0.249
-
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 May 29; 14(1):87.
Score: 0.242
-
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood. 2024 Aug 29; 144(9):955-963.
Score: 0.062